Literature DB >> 19444085

Epidemiological and genetic factors associated with ovarian cancer.

Monica R McLemore1, Christine Miaskowski, Bradley E Aouizerat, Lee-May Chen, Marylin J Dodd.   

Abstract

The purpose of this article was to provide a comprehensive review of the epidemiological and genetic factors associated with ovarian cancer. A more complete understanding of the determinants of ovarian cancer may lead to the development of better screening and detection methods for this disease. The first section of this article reviews current literature on screening and early detection of ovarian cancer. The second section reviews the epidemiology of ovarian cancer, specifically highlighting the risk factors associated with the development of this disease. The article concludes with a discussion of how oncology nurses can apply this information to improve patient care.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19444085      PMCID： PMC2891150          DOI： 10.1097/NCC.0b013e31819d30d6

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN： 0162-220X            Impact factor:   2.592


  58 in total

1.  Cancer killer may be "silent" no more.

Authors:  Renee Twombly
Journal:  J Natl Cancer Inst       Date:  2007-09-11       Impact factor: 13.506

2.  Cigarette smoking and epithelial ovarian cancer by histologic type.

Authors:  P A Marchbanks; H Wilson; E Bastos; D W Cramer; J M Schildkraut; H B Peterson
Journal:  Obstet Gynecol       Date:  2000-02       Impact factor: 7.661

3.  Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort.

Authors:  Susanna C Larsson; Leif Bergkvist; Alicja Wolk
Journal:  Am J Clin Nutr       Date:  2004-11       Impact factor: 7.045

4.  Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Authors:  Saundra S Buys; Edward Partridge; Mark H Greene; Philip C Prorok; Douglas Reding; Thomas L Riley; Patricia Hartge; Richard M Fagerstrom; Lawrence R Ragard; David Chia; Grant Izmirlian; Mona Fouad; Christine C Johnson; John K Gohagan
Journal:  Am J Obstet Gynecol       Date:  2005-11       Impact factor: 8.661

5.  Development of an ovarian cancer symptom index: possibilities for earlier detection.

Authors:  Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

Review 6.  Possible role of ovarian epithelial inflammation in ovarian cancer.

Authors:  R B Ness; C Cottreau
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

7.  Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Hans Nordlinder; Cecilia M Magnusson; Ingemar R Persson
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

8.  Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

Authors:  M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Dresher; Pamela Paley; Nicole Urban
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

9.  Role of prophylactic hysterectomy in patients at high risk for hereditary cancers.

Authors:  Jeannine A Villella; Madhu Parmar; Kathleen Donohue; Cathy Fahey; M Steven Piver; Kerry Rodabaugh
Journal:  Gynecol Oncol       Date:  2006-02-13       Impact factor: 5.482

Review 10.  Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.

Authors:  Karen H Lu
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375
View more
  18 in total

1.  Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.

Authors:  Aurelia Noske; Anne-Katrin Zimmermann; Rosmarie Caduff; Zsuzsanna Varga; Daniel Fink; Holger Moch; Glen Kristiansen
Journal:  Virchows Arch       Date:  2011-06-04       Impact factor: 4.064

2.  Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma.

Authors:  Jennifer M Watson; Photini F Rice; Samuel L Marion; Molly A Brewer; John R Davis; Jeffrey J Rodriguez; Urs Utzinger; Patricia B Hoyer; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2012-07       Impact factor: 3.170

3.  A prospective study of reproductive factors and exogenous hormone use in relation to ovarian cancer risk among Black women.

Authors:  Traci N Bethea; Julie R Palmer; Lucile L Adams-Campbell; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2016-12-27       Impact factor: 2.506

4.  Induction of apoptosis on ovarian adenocarcinoma cells, A2780 by tricyclohexylphosphanegold (I) mercaptobenzoate derivatives via intrinsic and extrinsic pathways.

Authors:  Kok Pian Ang; Pit Foong Chan; Roslida Abd Hamid
Journal:  J Biol Inorg Chem       Date:  2021-09-03       Impact factor: 3.358

5.  Serum CA125 concentration has inverse correlation with metabolic syndrome.

Authors:  Nam-Seok Joo; Kyu-Nam Kim; Kyung Soo Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

6.  Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.

Authors:  Ya Xie; Zheng Peng; Mingxing Shi; Mei Ji; Hongjun Guo; Huirong Shi
Journal:  Mol Med Rep       Date:  2014-08-14       Impact factor: 2.952

7.  Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer.

Authors:  Yimei Jin; Xin Xu; Xuemeng Wang; Henry Kuang; Michael Osterman; Shi Feng; Deqiang Han; Yu Wu; Mo Li; Hongyan Guo
Journal:  Oncotarget       Date:  2016-08-02

8.  Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells.

Authors:  Jerneja Kladnik; James P C Coverdale; Jakob Kljun; Hilke Burmeister; Petra Lippman; Francesca G Ellis; Alan M Jones; Ingo Ott; Isolda Romero-Canelón; Iztok Turel
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

9.  Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.

Authors:  Xiaoyong Li; Bo Shen; Qi Chen; Xiaohui Zhang; Yiqing Ye; Fengmei Wang; Xinmei Zhang
Journal:  BMC Cancer       Date:  2016-03-28       Impact factor: 4.430

Review 10.  A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Authors:  Luca Falzone; Giuseppa Scandurra; Valentina Lombardo; Giuseppe Gattuso; Alessandro Lavoro; Andrea Benedetto Distefano; Giuseppe Scibilia; Paolo Scollo
Journal:  Int J Oncol       Date:  2021-06-16       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.